Docetaxel is taxane-type antineoplastic agent structurally similar to taxol. It reversibly binds to polymerized tubulin inhibiting depolymerization. It induces apoptosis in a large number of tumor cells and is a clinically important anticancer agent.
Product Details
| Alternative Name: | Taxotere |
| |
| Formula: | C43H53NO14 |
| |
| MW: | 807.9 |
| |
| CAS: | 114977-28-5 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Appearance: | White solid. |
| |
| Solubility: | Soluble in DMSO (25mg/ml) or 100% ethanol (25mg/ml). |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Macrophage secretory IL-1β promotes docetaxel resistance in head and neck squamous carcinoma via SOD2/CAT ICAM1 signalin: C.Y Hsieh, et al.; JCI Insight
7, e157285 (2022),
Abstract;
Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression: A.R. Harris, et al.; BMC Cancer
18, 718 (2018),
Abstract;
Full Text
Direct modification of the 5-HT3 receptor current by some anticancer drugs: Y. Nakamura, et al.; Eur. J. Pharmacol.
821, 21 (2017),
Abstract;
Docetaxel in the management of prostate cancer: current standard of care and future directions: S. De Dosso & D.R. Berthold; Expert. Opin. Pharmacother.
9, 1969 (2008),
Abstract;
Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells: F. Fabbri, et al.; J. Cell Physiol.
217, 494 (2008),
Abstract;
Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines: M.D. Kars, et al.; Chemotherapy
54, 194 (2008),
Abstract;
RPN2 gene confers docetaxel resistance in breast cancer: K. Honma, et al.; Nat. Med.
14, 939 (2008),
Abstract;
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts: A. Cumashi, et al.; Cancer Lett.
270, 229 (2008),
Abstract;
